Aldeyra Therapeutics received fast track designation from the FDA for its drug candidate ADX-2191 targeting Retinitis Pigmentosa.

2 reports, 1 independent Updated Aug 19

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Aldeyra Therapeutics received fast track designation from the FDA for its drug candidate ADX-2191 targeting Retinitis Pigmentosa.

Who's involved

What this event is mainly about

FDA

Keep exploring

Part of

EMA granted Orphan Designation to Aldeyra's drug, following prior FDA designation. All 1 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Aug 19Business WireAldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa LEXINGTON, Mass., August 19, 2025--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALD
Jul 8Unknown outlet